Disrupted Brain Structure–Function Coupling and Its Mediating Effects on the Associations Between Cerebral Small Vessel Disease Burden and Cognitive Dysfunction
Na Wang, Lingfei Guo, Yian Gao, Chaofan Sui, Xinyue Zhang, Yuanyuan Wang, Yajie Fu, Nan Zhang, Yena Che, Hongwei Wen, Changhu Liang
{"title":"Disrupted Brain Structure–Function Coupling and Its Mediating Effects on the Associations Between Cerebral Small Vessel Disease Burden and Cognitive Dysfunction","authors":"Na Wang, Lingfei Guo, Yian Gao, Chaofan Sui, Xinyue Zhang, Yuanyuan Wang, Yajie Fu, Nan Zhang, Yena Che, Hongwei Wen, Changhu Liang","doi":"10.1111/cns.70604","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>We aimed to specify relationships among cerebral small vessel disease (CSVD) burden, cognitive dysfunction, and brain structure–function coupling changes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 108 patients with mild CSVD burden (CSVD-m), 53 patients with severe CSVD burden (CSVD-s), and 76 healthy controls (HC) were included in this study. The ratio of regional homogeneity (ReHo) or amplitude of low-frequency fluctuation (ALFF) to gray matter volume (GMV) was calculated as an indicator of voxel-wise structure–function coupling.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Significantly decreased or increased ReHo–GMV and ALFF–GMV coupling values in patients with severe CSVD burden were primarily found in several brain regions, and the disrupted structure–function coupling in the right putamen mediated the relationship between CSVD burden and cognitive dysfunction.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Brain structure–function coupling characterized by ReHo–GMV and ALFF–GMV mediated the cognitive dysfunction caused by CSVD and was an innovative and effective brain imaging indicator for exploring the association between CSVD burden and cognitive dysfunction.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 9","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12445204/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70604","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
We aimed to specify relationships among cerebral small vessel disease (CSVD) burden, cognitive dysfunction, and brain structure–function coupling changes.
Methods
A total of 108 patients with mild CSVD burden (CSVD-m), 53 patients with severe CSVD burden (CSVD-s), and 76 healthy controls (HC) were included in this study. The ratio of regional homogeneity (ReHo) or amplitude of low-frequency fluctuation (ALFF) to gray matter volume (GMV) was calculated as an indicator of voxel-wise structure–function coupling.
Results
Significantly decreased or increased ReHo–GMV and ALFF–GMV coupling values in patients with severe CSVD burden were primarily found in several brain regions, and the disrupted structure–function coupling in the right putamen mediated the relationship between CSVD burden and cognitive dysfunction.
Conclusions
Brain structure–function coupling characterized by ReHo–GMV and ALFF–GMV mediated the cognitive dysfunction caused by CSVD and was an innovative and effective brain imaging indicator for exploring the association between CSVD burden and cognitive dysfunction.
期刊介绍:
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.